Patent intelligence · US
US 9107887
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
Patent details — US 9107887
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 18, 2015
- Expiration
- Aug 13, 2035
- Applicant
- Provectus Pharmaceuticals, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K31/352, A61K31/365
Quick answer
US 9107887 (Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer) is held by Provectus Pharmaceuticals, Inc.. Status: granted. Granted Aug 18, 2015. Expires Aug 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K31/352, A61K31/365, A61K38/193, A61K38/20
More from Provectus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 9107887?
US 9107887 (Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer) is held by Provectus Pharmaceuticals, Inc.. Status: granted. Granted Aug 18, 2015. Expires Aug 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9107887?
Provectus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 9107887 expire?
Our index shows an expiration date of Aug 13, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.